How do Artificial Pancreas Device System (APDS) Work?
Artificial Pancreas Device System (APDS)
The FDA upholds its mission of
ensuring that medical devices are safe and effective by encouraging and
supporting medical device innovation. The FDA is assisting in the advancement
of the creation of an artificial pancreas device system, a cutting-edge device
that automatically measures blood glucose and administers the proper doses of insulin
to diabetics who use it. One or more of the following terms may be used to
describe an artificial pancreas device system: "closed-loop,"
"automated insulin delivery," or "autonomous system for glycemic
control."
Externally worn medical devices
called closed-loop artificial
pancreas device system (APDs) are being created to help people with
type 1 diabetes more automatically control their blood glucose levels. The
ground-breaking idea behind this new technology is that it is possible to
achieve hands-free, continuous glycemic control by utilising digital
communication technology and cutting-edge computer algorithms.
Existing wearable medical
devices, such as continuous glucose monitors (CGMs) and insulin pumps that
administer continuous subcutaneous insulin infusion therapy (CSII), can be used
to continuously manage type 1 diabetes. The low glucose suspend and predictive
low glucose suspend devices, also referred to as "first-generation"
APD systems, are two additional non-closed-loop artificial pancreas device
(APD) systems that are not fully automated. According to current research, Artificial
Pancreas Device System (APDS) may offer advantages over CSII
therapy alone in terms of extending the amount of time spent within the target
blood glucose range, decreasing the frequency of hypoglycemia, and improving
overnight control. Therefore, 1-3 APDs may soon provide a brand-new, largely
automated method of managing type 1 diabetes more successfully and
conveniently.
Comments
Post a Comment